Vaxcyte Stock Fundamentals
| PCVX Stock | USD 79.35 2.33 2.85% |
Vaxcyte fundamentals help investors to digest information that contributes to Vaxcyte's financial success or failures. It also enables traders to predict the movement of Vaxcyte Stock. The fundamental analysis module provides a way to measure Vaxcyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxcyte stock.
At this time, Vaxcyte's Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 73.3 M in 2025, whereas Interest Expense is likely to drop 0.00 in 2025. Vaxcyte | Select Account or Indicator |
Vaxcyte Company Return On Equity Analysis
Vaxcyte's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Vaxcyte Return On Equity | -0.21 |
Most of Vaxcyte's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxcyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Vaxcyte Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Vaxcyte has a Return On Equity of -0.2106. This is 99.12% lower than that of the Biotechnology sector and 99.42% lower than that of the Health Care industry. The return on equity for all United States stocks is 32.06% lower than that of the firm.
Vaxcyte Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vaxcyte's current stock value. Our valuation model uses many indicators to compare Vaxcyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vaxcyte competition to find correlations between indicators driving Vaxcyte's intrinsic value. More Info.Vaxcyte is regarded fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Vaxcyte's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vaxcyte's earnings, one of the primary drivers of an investment's value.Vaxcyte Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxcyte's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics of similar companies.Vaxcyte is currently under evaluation in return on equity category among its peers.
Vaxcyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vaxcyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vaxcyte's managers, analysts, and investors.Environmental | Governance | Social |
Vaxcyte Fundamentals
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 8.03 B | ||||
| Shares Outstanding | 124.64 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 99.29 % | ||||
| Number Of Shares Shorted | 13.53 M | ||||
| Price To Book | 2.98 X | ||||
| Gross Profit | (75 M) | ||||
| EBITDA | (464.88 M) | ||||
| Net Income | (402.27 M) | ||||
| Cash And Equivalents | 354.5 M | ||||
| Cash Per Share | 5.98 X | ||||
| Total Debt | 29.22 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 11.94 X | ||||
| Book Value Per Share | 27.47 X | ||||
| Cash Flow From Operations | (296.79 M) | ||||
| Short Ratio | 11.14 X | ||||
| Earnings Per Share | (4.60) X | ||||
| Price To Earnings To Growth | (11.32) X | ||||
| Target Price | 149.89 | ||||
| Number Of Employees | 254 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 10.18 B | ||||
| Total Asset | 1.41 B | ||||
| Retained Earnings | (924.39 M) | ||||
| Working Capital | 950.62 M | ||||
| Net Asset | 1.41 B |
About Vaxcyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -107.7 M | -102.3 M | |
| Cost Of Revenue | 86.2 M | 90.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.